107 related articles for article (PubMed ID: 36912151)
21. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
22. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Metcalfe KA; Finch A; Poll A; Horsman D; Kim-Sing C; Scott J; Royer R; Sun P; Narod SA
Br J Cancer; 2009 Jan; 100(2):421-5. PubMed ID: 19088722
[TBL] [Abstract][Full Text] [Related]
24. [GENOTYPE-PHENOTYPE CORRELATIONS BY SPECIFIC FOUNDER VARIANTS IN BRCA IN ISRAELI WOMEN].
Michaelson-Cohen R; Laitman Y; Kedar I; Baris-Feldman H; Reish O; Lieberman S; Bernstein-Molho R; Goldberg Y; Reznick Levi G; Gershoni R; Beller U; Levy-Lahad E; Catan R; Friedman E
Harefuah; 2023 Jun; 162(6):370-375. PubMed ID: 37394440
[TBL] [Abstract][Full Text] [Related]
25. Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
Machackova E; Claes K; Mikova M; Házová J; Sťahlová EH; Vasickova P; Trbusek M; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2019; 32(Supplementum2):51-71. PubMed ID: 31409081
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
El Saghir NS; Zgheib NK; Assi HA; Khoury KE; Bidet Y; Jaber SM; Charara RN; Farhat RA; Kreidieh FY; Decousus S; Romero P; Nemer GM; Salem Z; Shamseddine A; Tfayli A; Abbas J; Jamali F; Seoud M; Armstrong DK; Bignon YJ; Uhrhammer N
Oncologist; 2015 Apr; 20(4):357-64. PubMed ID: 25777348
[TBL] [Abstract][Full Text] [Related]
27. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
28. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
30. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
[TBL] [Abstract][Full Text] [Related]
31. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.
Kwong A; Ng EK; Wong CL; Law FB; Au T; Wong HN; Kurian AW; West DW; Ford JM; Ma ES
PLoS One; 2012; 7(9):e43994. PubMed ID: 22970155
[TBL] [Abstract][Full Text] [Related]
32. High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
Evans DG; van Veen EM; Byers HJ; Evans SJ; Burghel GJ; Woodward ER; Harkness EF; Eccles DM; Greville-Haygate SL; Ellingford JM; Bowers NL; Pereira M; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
J Med Genet; 2022 Feb; 59(2):115-121. PubMed ID: 33758026
[TBL] [Abstract][Full Text] [Related]
33. Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
Vos JR; Oosterwijk JC; Aalfs CM; Rookus MA; Adank MA; van der Hout AH; van Asperen CJ; Gómez Garcia EB; Mensenkamp AR; Jager A; Ausems MG; Mourits MJ; de Bock GH;
Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1251-8. PubMed ID: 27277847
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
35. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients.
Bang YJ; Kwon WK; Nam SJ; Kim SW; Chae BJ; Lee SK; Ryu JM; Kim JW; Yu J; Lee JE
Cancer Res Treat; 2022 Jul; 54(3):827-833. PubMed ID: 34645131
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
38. Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning.
Metcalfe KA; Eisen A; Wright F; Poll A; Candib A; McCready D; Cil T; Armel S; Silberman Y; Brennenstuhl S; Narod SA
Breast Cancer Res Treat; 2022 Feb; 191(3):631-641. PubMed ID: 34846626
[TBL] [Abstract][Full Text] [Related]
39. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
[TBL] [Abstract][Full Text] [Related]
40. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
